Breaking stories and in‑depth analysis: up‑to‑the‑minute global news on politics, business, technology, culture, and more—24/7, all in one place.
Jeremy’s insurance costs quadrupled this year, with his deductible soaring to $16,400. He’s delayed necessary medical care and now faces mounting bills, a situation Senator Amy Klobuchar says is “far too common across our country.” His experience is unfolding against a backdrop of renewed legislative efforts to protect genetic data privacy in the wake of 23andMe’s recent bankruptcy.
The surge in Jeremy’s healthcare expenses, although a personal hardship, highlights a broader concern about affordability and access to care, a point Klobuchar emphasized. The senator’s comments came as Congress considers the “Don’t Sell My DNA Act,” a bipartisan bill aimed at safeguarding sensitive genetic information held by companies like 23andMe.
23andMe filed for bankruptcy in February 2025, raising immediate questions about the fate of the genetic data collected from millions of customers. Concerns centered on the potential sale of that data to creditors, a scenario Klobuchar has publicly opposed. During a Senate Judiciary Subcommittee on Privacy, Technology, and the Law hearing in June 2025, Klobuchar questioned I. Glenn Cohen, a professor of law at Harvard Law School, about prioritizing consumer control over maximizing returns for creditors in bankruptcy proceedings. Cohen responded, stating it would be “nice for the creditors to get paid.”
The “Don’t Sell My DNA Act” is being spearheaded by Senators John Cornyn (R-TX) and Chuck Grassley (R-IA) alongside Klobuchar. The legislation seeks to amend Title 11 of the U.S. Code – the federal bankruptcy statute – to specifically include genetic information within the definition of “personally identifiable information.” Currently, that definition includes names, addresses, social security numbers, and financial data, but lacks explicit mention of genetic data, leaving it vulnerable during bankruptcy proceedings, according to Senate aides.
The bill’s introduction followed reports that 1.3 million 23andMe customers had requested deletion of their genetic data, with many initially facing technical issues fulfilling those requests. Joseph Selsavage, Interim CEO at 23andMe, testified before the Senate subcommittee that the company is now current on all deletion requests, following a surge in submissions prompted by the bankruptcy filing and guidance from state attorneys general.
The bankruptcy sale process for 23andMe concluded in July 2025, with TTAM Research Institute, formed by 23andMe’s co-founder and former CEO Anne Wojcicki, acquiring substantially all of the company’s assets. Despite challenges from the State of California, which sought a stay of the sale to protect California residents’ data, the Eighth Circuit Court of Appeals ultimately denied the state’s request, allowing the transaction to proceed. California’s appeal followed a ruling by the Bankruptcy Court that the state had failed to demonstrate irreparable injury to its residents.
While the sale has closed, the legislative debate surrounding genetic data privacy continues. The “Don’t Sell My DNA Act” remains pending in the Senate, with lawmakers continuing to grapple with the implications of rapidly evolving genetic technologies and the need to protect consumers’ sensitive information.